Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron <scp>BA</scp>.5 subvariant surge

Bronstein, Yotam; Levi, Shai; Herishanu, Yair

doi:10.1111/bjh.18807

Cited by 5 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early studies of COVID-19 and CLL have indicated high mortality rates at approximately 30% among hospitalized patients [1,3]. The majority of COVID-19 positive CLL patients required hospitalization, especially in the beginning of the pandemic [3][4][5]. The rates for intensive care unit (ICU) admission and intensive treatments with oxygen supplements and mechanical ventilation were also excessive compared to patients without a hematological disease [6].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study

Thau,

Poulsen,

Brieghel

et al. 2024

Preprint

View full text Add to dashboard Cite

Patients with chronic lymphocytic leukemia (CLL) are at high risk of developing severe COVID-19. The present study was undertaken to elucidate COVID-19 related morbidity and mortality in CLL patients treated with venetoclax. We present a single-center study of 108 patients with small lymphocytic lymphoma or CLL treated with venetoclax. Primary outcome was 30-day COVID-19 mortality. Secondary outcomes included COVID-19 severity and hospitalization rate. Forty-eight (44%) patients had PCR-verified SARS-COV-2 between March 2020 and January 2023. Thirty-six patients (75%) presented with asymptomatic/mild COVID-19 and 12 (25%) with severe/critical disease. The hospitalization rate was 46% with a 30-day mortality rate of only 4% and severe comorbidities as the primary cause of death. There was no significant difference in mortality when compared to venetoclax-naïve CLL patients (n = 90) from our single-center cohort with proven COVID-19. COVID-19 severity and mortality were similar before and during the Omicron era. High CIRS-scores (P < 0.02) and thrombocytopenia (P < 0.01) were more frequent in patients with severe/critical disease. In real-world data, most venetoclax treated patients presented with mild COVID-19. Hospitalization and mortality rates were low compared to data of general CLL populations. Our data indicate that venetoclax was a safe treatment option for CLL patients during the pandemic.

show abstract

Section: Introductionmentioning

confidence: 99%

COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study

Thau,

Poulsen,

Brieghel

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study

Thau,

Poulsen,

Brieghel

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

Patients with chronic lymphocytic leukemia (CLL) are at high risk of developing severe COVID-19. The present study was undertaken to elucidate COVID-19 related morbidity and mortality in CLL patients treated with venetoclax. We present a single-center study of 108 patients with small lymphocytic lymphoma or CLL treated with venetoclax. Primary outcome was 30-day COVID-19 mortality. Secondary outcomes included COVID-19 severity and hospitalization rate. Forty-eight (44%) patients had PCR-verified SARS-COV-2 between March 2020 and January 2023. Thirty-six patients (75%) presented with asymptomatic/mild COVID-19 and 12 (25%) with severe/critical disease. The hospitalization rate was 46% with a 30-day mortality rate of only 4% and severe comorbidities as the primary cause of death. COVID-19 severity and mortality were similar before and during the Omicron era. High CIRS-scores (P < 0.02) and thrombocytopenia (P < 0.01) were more frequent in patients with severe/critical disease. In real-world data, most venetoclax treated patients presented with mild COVID-19. Hospitalization and mortality rates were low compared to data of general CLL populations. Our data indicate that venetoclax was a safe treatment option for CLL patients during the pandemic.

show abstract

COVID-19 in patients with classic and variant hairy cell leukemia

Kreitman,

Yu,

James

et al. 2023

Blood Advances

View full text Add to dashboard Cite

Hairy cell leukemia (HCL), like its variant HCLv, is a B-cell malignancy associated with decreased humoral immunity. We prospectively monitored the largest cohort of HCL/HCLv patients to date (n=503) for COVID-19 by symptoms, antibody, PCR and/or antigen-positivity. Fifty percent (253 of 503) of the HCL/HCLv patients (238 HCL, 15 HCLv) had evidence of COVID-19, with 210 (83%) of 253 testing positive by PCR or rapid-antigen. Of 43 without positive tests, all had nucleocapsid antibodies indicating COVID-19 exposure, 7 recalled no symptoms, and 36 had mild symptoms but without a positive test. Of the 210 testing positive, 23, 46, 129 and 12 occurred in 2020, 2021, 2022 and 2023, respectively. Of 210 testing positive, 175 began treatment for HCL/HCLv 0.4-429 (median 66) months before, and 132 had their last dose of anti-CD20 Mab 0.2-229 (median 63) months before. Two patients died, including a young woman beginning rituximab 2 months after 1st-line cladribine before vaccine availability. Nearly all HCL/HCLv patients recovered uneventfully from COVID-19 including those without vaccination or those with significant immunosuppression and recent treatment. However, decreased normal B-cells from HCL or treatment was associated with lower spike antibody levels as a response to COVID-19 (p=0.0094) and longer recovery time (p=0.0036). Thus, in a large cohort of HCL/HCLv and the first to determine relationships between COVID-19 outcome and immune markers, mortality was relatively low (~1%), sequelae were uncommon, and recovery from COVID-19 was longer if normal B-cells were low after recent treatment.

show abstract

Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge

Cited by 5 publications

References 9 publications

COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study

COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study

COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study

COVID-19 in patients with classic and variant hairy cell leukemia

Contact Info

Product

Resources

About